First Time Loading...

Curaleaf Holdings Inc
TSX:CURA

Watchlist Manager
Curaleaf Holdings Inc Logo
Curaleaf Holdings Inc
TSX:CURA
Watchlist
Price: 7.35 CAD 0.55% Market Closed
Updated: May 9, 2024
Section:
 

Relative Value

The Relative Value of one CURA stock under the Base Case scenario is 9.45 CAD. Compared to the current market price of 7.35 CAD, Curaleaf Holdings Inc is Undervalued by 22%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CURA Relative Value
Base Case
9.45 CAD
Undervaluation 22%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

2.6
P/S
P/S
Price to Sales
2.6
vs History
51
vs Industry
46
Median 3Y
2.7
Median 5Y
2.7
Industry
2.5
Forward
2.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-19.6
Median 5Y
-19.6
Industry
23.4
Forward
-29.6
More Details
45.7
P/OCF
P/OCF
Price to OCF
45.7
vs History
48
vs Industry
9
Median 3Y
46.6
Median 5Y
46.6
Industry
17.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-11.4
Median 5Y
-11.4
Industry
23.6
More Details
3.3
P/B
P/B
Price to Book Value
3.3
vs History
28
vs Industry
24
Median 3Y
2.3
Median 5Y
2.3
Industry
2.1
More Details
3.2
EV/S
EV/S
Enterprise Value to Sales
3.2
vs History
51
vs Industry
37
Median 3Y
3.3
Median 5Y
3.3
Industry
2.6
Forward
2.9
More Details
6.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.9
vs History
58
vs Industry
32
Median 3Y
7.8
Median 5Y
7.8
Industry
5.2
More Details
17.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.9
vs History
23
vs Industry
22
Median 3Y
-19.4
Median 5Y
-19.4
Industry
13.7
Forward
11.9
More Details
99.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
99.5
vs History
12
vs Industry
4
Median 3Y
-12.1
Median 5Y
-12.1
Industry
17.2
Forward
32.8
More Details
56.7
EV/OCF
EV/OCF
Enterprise Value to OCF
56.7
vs History
48
vs Industry
7
Median 3Y
57.5
Median 5Y
57.5
Industry
16.2
More Details
860.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
860.5
vs History
7
vs Industry
1
Median 3Y
-36.2
Median 5Y
-36.2
Industry
17.8
More Details
1.5
EV/IC
EV/IC
Enterprise Value to IC
1.5
vs History
43
vs Industry
48
Median 3Y
1.4
Median 5Y
1.4
Industry
2
More Details

Multiples Across Competitors

CURA Competitors Multiples
Curaleaf Holdings Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Curaleaf Holdings Inc
TSX:CURA
4.7B CAD 2.6 -12.2 17.9 99.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
733.3B USD 20.4 119.5 58.5 66.6
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.1 44.1 32.9 36.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
360.6B USD 4.2 9.4 11.5 15.1
US
Merck & Co Inc
NYSE:MRK
330.2B USD 5.4 143.2 35.7 58.2
UK
AstraZeneca PLC
LSE:AZN
191.2B GBP 5 37.7 174.5 278.4
CH
Roche Holding AG
SIX:ROG
177.2B CHF 3 15.4 8.8 10.4
CH
Novartis AG
SIX:NOVN
177.1B CHF 3.3 11.1 8.5 12.4
US
Pfizer Inc
NYSE:PFE
159.1B USD 2.9 -514.9 12.8 20.3
P/E Multiple
Earnings Growth
US
Curaleaf Holdings Inc
TSX:CURA
Average P/E: 54.3
Negative Multiple: -12.2 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
119.5
346%
DK
Novo Nordisk A/S
CSE:NOVO B
44.1
84%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
US
Johnson & Johnson
NYSE:JNJ
9.4
-20%
US
Merck & Co Inc
NYSE:MRK
143.2
7 454%
UK
AstraZeneca PLC
LSE:AZN
37.7
168%
CH
Roche Holding AG
SIX:ROG
15.4
26%
CH
Novartis AG
SIX:NOVN
11.1
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -514.9
680%

See Also

Summary
CURA intrinsic value, competitors valuation, and company profile.
DCF Valuation
CURA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CURA stock valuation using valuation multiples.
Wall Street Estimates
CURA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CURA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 135,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.